The Impact of Comprehensive Pharmaceutical Services on Medication Safety in Gynaecological Oncology Chemotherapy Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 629
- 试验地点
- 1
- 主要终点
- Degree of myelosuppression
研究概览
简要总结
What was studied? We wanted to see whether having pharmacists closely involved in cancer care improves medication safety and reduces severe side effects for patients with gynecologic cancers (like ovarian or uterine cancer) during chemotherapy.
How was the study done?
Who participated? Patients receiving chemotherapy at Peking University First Hospital's Gynecologic Oncology Ward (September 2022-September 2024).
Two groups compared:
Standard care group: Pharmacists provided routine pharmaceutical services.
Full pharmacy care group: Pharmacists provided ongoing support, including:
Checking medications for safety.
Teaching patients how to manage side effects.
Answering questions about drugs.
Helping manage reactions like nausea or low white blood cells.
What was measured? Severe side effects (e.g., extreme nausea, appetite loss), how well doctors prescribed and monitored medications to boost white blood cells, and unplanned hospital stays.
Key findings:
Patients with full pharmacy care had:
Fewer severe side effects: Less extreme nausea, appetite loss, and dangerously low white blood cell counts.
Better management of blood cell-boosting medications: Doctors followed guidelines more closely, and patients received proper monitoring.
Fewer unplanned hospital visits: Likely due to better side effect prevention and early intervention.
Why does this matter?
For patients: Pharmacist support during chemotherapy may help you avoid severe side effects and reduce unexpected hospital stays.
For families: Knowing pharmacists are actively involved can provide reassurance about your loved one's medication safety.
For healthcare teams: Structured pharmacist collaboration improves adherence to treatment guidelines and patient outcomes.
Takeaway:
Full pharmacy care throughout chemotherapy helps protect patients' safety, reduces severe reactions, and supports smoother treatment journeys.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with gynaecologic malignancies such as ovarian cancer, cervical cancer, endometrial cancer, or gestational trophoblastic tumours.
- •Patients who received one of the following chemotherapy regimens: taxane monotherapy or combination therapy, anthracycline monotherapy or combination therapy, platinum-based monotherapy or combination therapy. These chemotherapy regimens could be combined with targeted therapy or immunotherapy.
排除标准
- •Patients treated with chemotherapy regimens outside those specified in the inclusion criteria.
- •Patients who received only targeted therapy, immunotherapy, endocrine therapy, bone-modifying therapy, or combinations of these treatments.
结局指标
主要结局
Degree of myelosuppression
时间窗: From enrollment to the end of treatment at 3 weeks
次要结局
- Degree of adverse gastrointestinal reactions(From enrollment to the end of treatment at 3 weeks)
- Readmission rate(From enrollment to the end of treatment at 3 weeks)
研究者
Zhiqi Zhang
Pharmacist
Peking University First Hospital